William Blair
http://www.williamblair.comWilliam Blair & Company, L.L.C. is a Chicago-based investment firm offering investment banking, asset management, equity research, institutional and private brokerage, and private capital to individual, institutional, and issuing clients. Since 1935, it has been committed to helping clients achieve their financial objectives.
View Older Stories View More Recent Stories
-
Autolus Announces Proposed Public Offering in the United States
-
Saratoga Investment Corp. Prices Public Offering of $52.5 Million 8.125% Notes Due 2027
-
Saratoga Investment Corp. Prices Public Offering of $52.5 Million 8.125% Notes Due 2027
-
Saratoga Investment Corp. Announces Offering of Notes and BBB+ Investment Grade Rating from Egan-Jones Ratings Company
-
Saratoga Investment Corp. Announces Offering of Notes and BBB+ Investment Grade Rating from Egan-Jones Ratings Company
-
First Women’s Bank announces new Mission Partners Airbnb, BCG, Principal®, Salesforce and Envestnet have joined the Bank to help close the gender gap in access to capital
-
William Blair on Wayfair (W): 'Early Signs of Strong Holiday Demand Suggests Upside in the Upcoming Fourth Quarter'
-
Form 497K WILLIAM BLAIR FUNDS
-
Form 497K WILLIAM BLAIR FUNDS
-
Form 497 WILLIAM BLAIR FUNDS
-
William Blair Reiterates Outperform Rating on Gogo (GOGO) as Business Jet Traffic Hits a Five-Month High
-
NewAmsterdam Pharma (NAMS) Debuts as Publicly Traded Company
-
NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential
-
NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential
-
William Blair Upgrades Neogen (NEOG) to Outperform
-
Biodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Sep 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Sep 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Sep 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Sep 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Sep 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Sep 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Sep 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Sep 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Sep 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Sep 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Sep 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Sep 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Sep 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Sep 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Sep 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Sep 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Sep 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Sep 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Sep 30
-
Privia Health Group, Inc (PRVA) Prices 5M Share Secondary Offering at $23.50/sh
-
Biodesix (BDSX) Prices Upsized 30.5M Share Offering at $1.15/sh
-
Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock
-
Privia Health Announces Pricing of Secondary Offering
-
Biodesix Inc. (BDSX) Announces Proposed $30M Stock Offering
-
Biodesix Announces Proposed Public Offering of Common Stock
-
Millennium Trust Names Dan Laszlo Chief Executive Officer
-
Privia Health Group (PRVA) Announces 5M Share Secondary Offering by Selling Stockholders
-
Privia Health Announces Secondary Offering
-
Clarivate (CLVT) gains on new Elliott stake, but change is already taking place
-
Frazier Lifesciences Acquisition Corporation Shareholders Approve Business Combination with NewAmsterdam Pharma Holding B.V.
-
Palantir (PLTR) investors missed Fast Radius bankruptcy news - William Blair
-
UPDATE: William Blair Starts Janux Therapeutics (JANX) at Outperform
-
William Blair Downgrades Science 37 (SNCE) to Market Perform
-
William Blair Starts Genmab A/S (GMAB) at Market Perform

